Business Insider

Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal PatchEuropean market represents latest opportunity for anti-nausea transdermal ...

VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of the market ...
Business Insider

Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch

VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on ...
Monthly Prescribing Reference

FDA Alert Warns of Possible Hyperthermia With Antinausea Patch

The time from patch application to hyperthermia onset was typically less than 72 hours. The antinausea patch Transderm Scōp (scopolamine transdermal system) has been linked to several cases of ...
Reuters

Aequus announces positive results for proof of concept clinical trial of anti-nausea patch

* Says co owns global rights to program,will look to find a strategic partner to advance towards commercialization in major markets Source text for Eikon: Further company coverage: Sign up here. Our ...
Reuters

Aequus gets approval from Health Canada to initiate proof of concept clinical trial of anti-nausea patch

* Aequus Pharmaceuticals Inc - preparing for a pre-investigational new drug (pre-IND) meeting with US Food And Drug Administration Source text for Eikon: Further company coverage: ...